Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
UNCY Unicycive Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: UNCY
Price (delayed)
$0.775
Market cap
$93.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$74.27M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic
Highlights
The equity has surged by 146% year-on-year and by 52% since the previous quarter
The company's EPS has surged by 81% YoY and by 59% QoQ
UNCY's quick ratio is down by 27% year-on-year but it is up by 10% since the previous quarter
Key stats
What are the main financial stats of UNCY
Market
Valuations
Earnings
Shares outstanding
120.63M
Market cap
$93.49M
Enterprise value
$74.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$30.9M
Net income
-$15.26M
EBIT
-$15.19M
EBITDA
-$14.91M
Free cash flow
-$31.1M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.51
Free cash flow per share
-$0.27
Book value per share
$0.09
Revenue per share
$0
TBVPS
$0.24
Total assets
$27.95M
Total liabilities
$16.68M
Debt
$548,000
Equity
$11.27M
Working capital
$10.67M
Debt to equity
0.05
Current ratio
1.64
Quick ratio
1.19
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-61.8%
Return on equity
-278.4%
Return on invested capital
N/A
Return on capital employed
-134.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UNCY stock price
How has the Unicycive Therapeutics stock price performed over time
Intraday
1.57%
1 week
26.86%
1 month
18.85%
1 year
-3.8%
YTD
-2.42%
QTD
34.81%
Financial performance
How have Unicycive Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.9M
Net income
-$15.26M
Gross margin
N/A
Net margin
N/A
UNCY's net income has surged by 59% year-on-year and by 58% since the previous quarter
The company's operating income fell by 20% YoY but it rose by 3.8% QoQ
Price vs fundamentals
How does UNCY's price correlate with its fundamentals
Growth
What is Unicycive Therapeutics's growth rate over time
Valuation
What is Unicycive Therapeutics stock price valuation
P/E
N/A
P/B
8.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 81% YoY and by 59% QoQ
The equity has surged by 146% year-on-year and by 52% since the previous quarter
Efficiency
How efficient is Unicycive Therapeutics business performance
UNCY's ROA has soared by 56% YoY and by 32% QoQ
Dividends
What is UNCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UNCY.
Financial health
How did Unicycive Therapeutics financials performed over time
Unicycive Therapeutics's total assets is 68% more than its total liabilities
Unicycive Therapeutics's total assets has decreased by 47% YoY and by 12% from the previous quarter
Unicycive Therapeutics's total liabilities has decreased by 46% YoY and by 31% from the previous quarter
UNCY's debt is 95% smaller than its equity
The equity has surged by 146% year-on-year and by 52% since the previous quarter
Unicycive Therapeutics's debt to equity has decreased by 44% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.